🔍

Q-Line Biotech Limited (QLINE)

📊 NSE: QLINE 🏢 Medical Equipment & Supplies 📢 Latest filing: 08 Oct 2026

QLINE delivery percentage

NSE end-of-day data for Thu, 22 Oct 2026

On Thu, 22 Oct 2026, 80.28% of the QLINE shares traded on NSE were taken to delivery, against the stock's own 20-session average of 63.29%. Delivery was unusually high while the price barely moved (-0.60%).

80.28%Delivery, 22 Oct

63.29%Own 20-session average

1.0×Volume vs its average

₹569.00NSE close · -0.60%

Delivery in the last 5 sessions: 68.6% · 49.6% · 68.3% · 58.6% · 80.3%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Q-Line Biotech Submits Reg 74(5) Dematerialisation Certificate for Q2 Ended September 30, 2026

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 08 Oct 2026, 06:58 PM

Q-Line Biotech Limited has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026. The certificate issued by Registrar and Share Transfer Agent (RTA) Purva Sharegistry (India) Private Limited confirms that security certificates received for dematerialisation during the period were processed, confirmed or rejected, and properly mutilated/cancelled. This filing is a standard quarterly regulatory compliance disclosure with no operational or financial impact.

Compliance certificate submitted under Regulation 74(5) of SEBI Regulations, 2018
Covers the quarter and month ended September 30, 2026
Issued by RTA Purva Sharegistry (India) Private Limited on October 01, 2026
Filing submitted to the National Stock Exchange on October 08, 2026

💡 No investor action is required as this is a recurring regulatory formality. Track upcoming quarterly earnings disclosures for fundamental business updates.

Q-Line Biotech Shareholders Approve All 4 Resolutions at 16th AGM with 74.01% Turnout

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 01 Oct 2026, 06:36 PM

Q-Line Biotech Limited has declared the voting results and scrutinizer's report for its 16th Annual General Meeting held on September 30, 2026. A total of 1,72,65,300 votes were polled across 2,33,28,199 total shares, representing a 74.01% turnout. All four ordinary resolutions, including the adoption of FY audited statements, re-appointment of retiring directors, and remuneration ratification for the cost auditor, were passed with requisite majority (>99.99% support).

All 4 ordinary resolutions approved with requisite majority at the 16th AGM held on September 30, 2026
Overall voter turnout was 74.0104%, representing 1,72,65,300 polled shares out of 2,33,28,199 total shares
Resolution 1 (adoption of audited financial statements) passed with 100% votes in favor
Re-appointment of directors Ajay Kumar Mahanty (100% favor) and Kuldeep Chowdhry (99.993% favor) approved
Cost auditor remuneration for FY 2026-27 approved with 99.9954% votes in favor

💡 Track the upcoming quarterly financial results and execution updates, as this announcement reflects routine AGM business as usual.

Q-Line Biotech Shareholders Approve All 4 Resolutions at 16th AGM with Near 100% Majority

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 01 Oct 2026, 06:03 PM

Q-Line Biotech Limited has submitted the Scrutinizer's Report for its 16th Annual General Meeting held on September 30, 2026. All four ordinary resolutions placed before the shareholders were passed with an overwhelming majority (near 100% approval). The approved agenda included adopting standalone and consolidated audited financials for FY26, re-appointing directors Ajay Kumar Mahanty and Kuldeep Chowdhry, and ratifying the cost auditor's remuneration for FY27.

All 4 ordinary resolutions approved with requisite majority at the 16th AGM held on September 30, 2026
Adoption of FY26 standalone and consolidated financial statements passed with 100% of 17,265,300 votes in favour
Re-appointment of director Kuldeep Chowdhry passed with 99.9930% votes in favour (1,200 votes against)
Ratification of cost auditor remuneration for FY 2026-27 approved with 99.9954% votes in favour

💡 This is a standard post-AGM statutory filing; investors should track upcoming Q2 FY27 earnings releases and operational updates.

Q-Line Biotech Schedules 16th AGM on Sept 30, 2026; Issues Notice For Bounced Emails

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 11 Sep 2026, 07:21 PM

Q-Line Biotech Limited has issued a dispatch notice containing web links for its FY 2025-26 Annual Report and 16th AGM Notice to shareholders whose registered emails bounced back. The 16th AGM is scheduled to be held physically on September 30, 2026, at 4:00 P.M. in Lucknow. The cut-off date to determine voting eligibility is September 23, 2026, with remote e-voting running from September 27 to September 29, 2026.

16th Annual General Meeting to be held on September 30, 2026, at 4:00 P.M. IST in physical mode in Lucknow
Cut-off date for remote e-voting and voting eligibility set as September 23, 2026
Remote e-voting period opens on September 27, 2026 (9:00 A.M.) and closes on September 29, 2026 (5:00 P.M.)
Letter dispatched under Regulation 36(1)(b) for shareholders with undelivered/bounced email addresses

💡 Eligible shareholders should verify their voting rights before the September 23, 2026 cut-off date and update their KYC/email details with the RTA.

Q-Line Biotech Issues Corrigendum Correcting 16th AGM Typographical Error

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 08 Sep 2026, 05:28 PM

Q-Line Biotech Limited has issued a corrigendum regarding its filings dated September 07, 2026. The company clarified that due to a typographical error, the 16th Annual General Meeting was incorrectly labeled as the 37th AGM in the subject lines of two exchange intimations. There are no changes to the contents of the Annual Report for FY 2025-26 or the Notice of the AGM itself.

Clarified typographical error referring to the 37th AGM instead of the 16th AGM
Pertains to two previous intimations submitted on September 07, 2026
Annual Report FY 2025-26 and AGM notice contents remain completely unchanged

💡 No action is required as this is a minor administrative correction regarding the AGM numbering.

Q-Line Biotech Submits FY26 Annual Report; 16th AGM Scheduled for September 30, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 07 Sep 2026, 06:14 PM

Q-Line Biotech Limited has submitted its Annual Report for the financial year 2025-26 along with the Notice convening its 16th Annual General Meeting (AGM). The AGM is scheduled to be held in physical mode on September 30, 2026, at Lucknow. Key agenda items include the adoption of FY26 standalone and consolidated audited financial statements, director retirements by rotation, and ratification of cost auditor remuneration of ₹1,20,000 for FY27. In consolidated notes, the company noted that losses attributable to minority shareholders in certain subsidiaries have exceeded their equity and were absorbed by the parent company.

16th Annual General Meeting scheduled for September 30, 2026, at Lucknow
Adoption of Standalone and Consolidated Audited Financial Statements for FY ended March 31, 2026
Ratification of remuneration of ₹1,20,000 plus taxes for Cost Auditor M/s P S P & Associates for FY 2026-27
Subsidiary minority interest presented at NIL as excess losses were absorbed by the parent company under AS 21

💡 Investors should review the detailed consolidated balance sheet and operational performance disclosures in the Annual Report, and monitor voting outcomes following the AGM on September 30, 2026.

Q-Line Biotech Submits FY2025-26 Annual Report and Schedules 16th AGM for September 30, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 07 Sep 2026, 06:12 PM

Q-Line Biotech Limited has submitted its Annual Report for the financial year 2025-26 along with the notice for its 16th Annual General Meeting (AGM). The AGM is scheduled to be held in physical mode on September 30, 2026, in Lucknow. Key agenda items include the adoption of standalone and consolidated audited financial statements, re-appointment of directors retiring by rotation, and ratification of cost auditor remuneration of ₹1,20,000 for FY2026-27. The company noted that charges relating to lenders Vivriti Capital Limited and Tata Capital Limited were not yet registered with the ROC as of the signing date.

16th Annual General Meeting scheduled for September 30, 2026, at Lucknow in physical mode
Approval sought for cost auditor remuneration of ₹1,20,000 plus taxes for FY2026-27
Parent company absorbed losses of subsidiaries exceeding minority interest as per AS 21
Unregistered ROC charges pending with Vivriti Capital Limited and Tata Capital Limited as of report date

💡 Review the full FY26 disclosures and notes to accounts in the annual report, and monitor shareholder voting outcomes following the AGM on September 30, 2026.

Q-Line Biotech Convenes 16th AGM on September 30, 2026; Remote E-Voting from September 27

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Sep 2026, 05:38 PM

Q-Line Biotech Limited has issued the notice for its 16th Annual General Meeting (AGM) scheduled for September 30, 2026, at Lucknow. The cut-off date for e-voting eligibility has been fixed as September 23, 2026, with the remote voting window active between September 27 and September 29, 2026. Key agenda items include the adoption of FY2025-26 standalone and consolidated financial statements, re-appointment of retiring directors, and ratification of cost auditor remuneration of ₹1,20,000.

16th Annual General Meeting to be held on Wednesday, September 30, 2026, at 04:00 PM IST in physical mode at Lucknow.
Cut-off date for determining member eligibility for remote e-voting is September 23, 2026.
Remote e-voting commences on September 27, 2026 (9:00 AM IST) and concludes on September 29, 2026 (5:00 PM IST).
Proposed ratification of ₹1,20,000 remuneration plus taxes for Cost Auditor M/s P S P & Associates for FY 2026-27.

💡 Eligible shareholders as of September 23, 2026, can review the FY2025-26 Annual Report and participate in voting through CDSL remote e-voting between September 27 and September 29, 2026.

Q-Line Biotech Schedules 16th AGM for September 30, 2026; Sets Cut-Off Date to Sept 23

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 05 Sep 2026, 06:15 PM

Q-Line Biotech Limited held its Board of Directors meeting on September 05, 2026, approving the Board's Report and Management Discussion and Analysis Report for the financial year ended March 31, 2026. The 16th Annual General Meeting (AGM) has been scheduled for September 30, 2026, via physical mode in Lucknow. The cut-off date to determine member eligibility for e-voting is set as September 23, 2026. Additionally, the Board recommended the re-appointment of two Whole-Time Directors retiring by rotation and re-appointed M/s P S P & Associates as Cost Auditor for FY 2026-27.

16th Annual General Meeting scheduled for September 30, 2026, at 04:00 PM IST in Lucknow
Cut-off date for remote e-voting and AGM voting fixed as September 23, 2026
Remote e-voting window active from September 27, 2026 (9:00 AM) to September 29, 2026 (5:00 PM)
Recommended re-appointment of Whole Time Directors Mr. Ajay Kumar Mahanty and Mr. Kuldeep Chowdhry
Re-appointed M/s P S P & Associates as Cost Auditor for FY 2026-27

💡 Eligible shareholders holding shares on the cut-off date (September 23, 2026) can participate in the e-voting process between September 27 and September 29, 2026.

Q-Line Biotech Cuts Royalty Cost by 25% in Revised 5-Year Pact with Boule Medical

🟢 POSITIVE ⭐ 6/10

OTHER 📅 02 Sep 2026, 05:54 PM

Q-Line Biotech Limited has executed an Amended and Restated License Agreement with Sweden-based Boule Medical AB for diagnostic reagents, consumables, and haematology analyser platforms. Under the revised terms, the license/royalty payable by Q-Line to Boule is reduced by 25%, effective retroactively from July 01, 2026. The agreement has an initial term of 5 years, extendable by another 5 years upon mutual consent. The revised arrangement also provides rationalised minimum purchase commitments, revised instrument license fees, and extended payment terms to improve cost competitiveness in institutional tenders.

25% reduction in license/royalty costs payable by Q-Line to Boule Medical AB
Revised commercial and royalty terms effective retroactively from July 01, 2026
Initial contract tenure set at 5 years, extendable for up to an additional 5 years
Agreement incorporates rationalised minimum purchase commitments, extended payment terms, and volume-linked benefits

💡 Monitor upcoming quarterly earnings to assess margin expansion in the diagnostic consumables segment following the 25% royalty reduction.

CARE Assigns 'CARE A-; Stable/A2+' Ratings to Rs 221.30 Cr Bank Facilities of Q-Line Biotech

🟢 POSITIVE ⭐ 5/10

OTHER 📅 22 Aug 2026, 05:12 PM

CARE Ratings has assigned fresh credit ratings to Q-Line Biotech Limited's bank facilities totaling Rs 221.30 crore. Long-term facilities of Rs 20.00 crore were assigned 'CARE A-; Stable', while short-term facilities of Rs 16.00 crore received 'CARE A2+'. Long-term/short-term facilities of Rs 185.30 crore (including Rs 61.55 crore in proposed limits) were assigned 'CARE A-; Stable / CARE A2+'. The ratings reflect an investment-grade profile that can assist the company in maintaining competitive borrowing costs.

CARE Ratings assigned 'CARE A-; Stable' to Rs 20.00 crore long-term term loan facilities from Bank of Baroda
Assigned 'CARE A-; Stable / CARE A2+' to Rs 185.30 crore long-term/short-term facilities, including Rs 123.75 crore fund-based limits
Assigned 'CARE A2+' rating to Rs 16.00 crore short-term non-fund based limits from HDFC Bank
Total bank facilities evaluated stand at Rs 221.30 crore, with Rs 61.55 crore categorized as proposed limits

💡 Track the upcoming detailed rating rationale from CARE Ratings for granular insights on debt coverage metrics, working capital cycle, and revenue growth drivers.

Q-Line Biotech Reports Nil Share Dematerialization for Quarter Ended June 30, 2026

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 27 Jul 2026, 06:49 PM

Q-Line Biotech Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The report, issued by Purva Sharegistry (India) Pvt. Ltd., confirms that no physical share certificates were received for dematerialization during the period from April 1, 2026, to June 30, 2026. This is a routine administrative filing confirming the maintenance of the company's share register and compliance with depository timelines.

Zero (NIL) shares were dematerialized during the quarter ended June 30, 2026
Compliance confirmed for the period starting April 1, 2026, to June 30, 2026
Registrar and Share Transfer Agent (RTA) confirmed as Purva Sharegistry (India) Pvt. Ltd.
Filing submitted under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018

💡 This is a routine procedural filing with no impact on business operations. Investors should monitor upcoming quarterly financial results for fundamental performance updates.

Q-Line Biotech reports NIL share dematerialization for quarter ended June 30, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Jul 2026, 06:03 PM

Q-Line Biotech Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Purva Sharegistry (India) Pvt. Ltd., confirms that all dematerialization requests for the quarter ended June 30, 2026, were processed within prescribed timelines. Notably, the company reported zero (NIL) share certificates were dematerialized during this period. This is a standard administrative filing with no impact on business operations or financials.

Reporting period covers the quarter from April 1, 2026, to June 30, 2026
Total number of shares dematerialized during the quarter was NIL
Compliance confirmed by Registrar and Share Transfer Agent, Purva Sharegistry (India) Pvt. Ltd.
The filing confirms the substitution of depository names in the register of members where applicable

💡 No action is required as this is a routine regulatory filing confirming the integrity of the company's shareholding records.

View All QLINE Announcements on Live Market Tracking →